Este IPO no ha sido traducido a su idioma todavía — mostrando la versión en inglés. [en]
METIS TECHBIO-P logo

METIS TECHBIO-P

07666 · HKEX
Listed

Materia Medica Tech is a biotechnology company driven by artificial intelligence (AI) and innovative nanomaterial technologies.

Listed

IPO Timeline

  1. AbiertoMay 05
  2. CerrarMay 08
  3. SuscripciónMay 12
  4. PagoMay 13
  5. ListaMay 13

Principales hechos

Precio del número

HKD 10.50

Min Entry Fee

HKD 5,302.94

Acciones publicadas

201.23M

Tamaño del lote

500

Total Raise

HKD 2112.9M

Estimación de la capacidad de mercado

HKD 12.10B

Asignación pública

5.0%

International Placement

95.0%

Panorama general de las empresas

Materia Medica Tech is a biotechnology company driven by artificial intelligence (AI) and innovative nanomaterial technologies. It focuses on leveraging targeted drug delivery and drug discovery technologies to accelerate patients’ access to innovative therapies across key disease areas.

Uso de Proceeds

1、Approximately HK$988.5 million (about 50.0%) will be used to support the core technology research, development and advancement of the Company’s artificial intelligence infrastructure and AI-driven nanomaterial platform;

2、Approximately HK$395.4 million (about 20.0%) will be allocated to the ongoing and planned clinical trials within the Company’s artificial intelligence product pipeline;

3、Approximately HK$197.7 million (about 10.0%) will be utilised to develop the Company’s animal health and anti-aging solutions, and expand AI-empowered solutions into such high-growth sectors;

4、Approximately HK$197.7 million (about 10.0%) will be allocated to support the Company’s growth strategy of building a global AI-driven nanomaterial ecosystem;

5、Approximately HK$197.7 million (about 10.0%) will be used as working capital and for other general corporate purposes.

Patrocinio del registro de seguimiento

Se están renovando los datos de registro de pistas.

Intermediarios " Documentos "

Patrocinadores

  • 富瑞金融集團香港有限公司
  • 德意志證券亞洲有限公司
  • 中信證券(香港)有限公司

Underwriters

  • 富瑞金融集團香港有限公司
  • 德意志銀行香港分行
  • 中信里昂證券有限公司
  • 招銀國際融資有限公司
  • 富途證券國際(香港)有限公司

Prospectus PDF

Prospectus PDF →

Cornerstone Investors

  • BlackRock Funds
  • UBS Asset Management (Singapore) Ltd.
  • 国风投创新投资基金股份有限公司
  • Mirae Asset Securities (HK) Limited
  • HHLR Advisors, Ltd.
  • Huadeng Technology Piovt Ventures Ltd
  • Isometry Global Master Fund, L.P.
  • Deerfield Management Company, L.P.
  • RTW Funds
  • Arc Avenue Asset Management Pte. Ltd.
  • 华夏基金(香港)有限公司
  • 富国基金管理有限公司
  • 工银瑞信基金管理有限公司
  • 广发基金管理有限公司
  • Sage Partners Master Fund
  • Lake Bleu Prime Healthcare Master Fund Limited
  • Lazurite Hime L.P.
  • 工银理财有限责任公司

Total

0

54.8% of placement

BBX no participa en el proceso de asignación para cualquier IPO enumerado en esta página. Esta página es sólo para fines informativos y no es asesoramiento de inversión.